Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer
Stopped early · Phase 2
Conditions studied: Stage IV Pancreatic Cancer
In brief
Current therapies for Stage IV Pancreatic Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV Pancreatic Cancer. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Stage IV Pancreatic Cancer.
Key facts
- Study ID
- NCT00003531
- Run by
- Burzynski Research Institute
- People needed
- 15
- Starts
- 1996-04-10
- Expected to finish
- 2005-07-18
- Last updated by the study team
- 2021-01-07
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Burzynski Clinic — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.